Further research into intralesional IFNγ for advanced melanoma was scarce for years, until a small-scale study using a melanoma vaccine (containing class I MHC-restricted melanoma neoantigens) bolstered with IFNγ was completed [40]. The gene discussed is IFNG; the disease is melanoma.